{
    "clinical_study": {
        "@rank": "120836", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra\n      (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who\n      completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical\n      response to RoActemra/Actemra in the core study will be eligible to receive\n      RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment\n      is 104 weeks."
        }, 
        "brief_title": "A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with\n             at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in\n             WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued\n             treatment\n\n          -  Scheduled to receive first RoActemra/Actemra infusion in this study between 4 and 6\n             weeks after the last IV infusion in the core study\n\n          -  Females of child-bearing potential and males with female partners of child-bearing\n             potential must agree to use effective contraception as defined by protocol\n\n        Exclusion Criteria:\n\n          -  Patients with, according to investigator judgment,  not satisfactory benefit from\n             RoActemra/Actemra therapy within WA19977\n\n          -  Treatment with any investigational agent since the last administration of study drug\n             in the core study WA19977 or current participation in another clinical trial except\n             WA19977\n\n          -  Patient developed any other autoimmune rheumatic disease or overlap syndrome other\n             than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or\n             negative JIA or extended oligoarticular JIA\n\n          -  Patient is pregnant , lactating, or intending to become pregnant during the study and\n             up to 12 weeks after the last administration of study drug\n\n          -  Any significant concomitant disease or medical or surgical condition\n\n          -  History of significant allergic or infusion reactions to prior biologic therapy\n\n          -  Known current active acute, subacute, chronic or history of recurrent infection;\n             patients suffering from ongoing active infections with Epstein Barr virus, herpes\n             zoster or recurrent history of urinary tract infection can be included after the\n             (acute) infection has been excluded or subsided\n\n          -  Positive for latent tuberculosis (TB)\n\n          -  Currently active asthma for which the patient has required the use of oral or\n             parenteral corticosteroids for >/= 2 weeks within 6 months prior to entering the\n             study\n\n          -  Inadequate hepatic, renal or bone marrow function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "9 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667471", 
            "org_study_id": "ML25756", 
            "secondary_id": "2011-001097-25"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "8 mg/kg iv every 4 weeks, 104 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bremen", 
                        "country": "Germany", 
                        "zip": "28177"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt/Main", 
                        "country": "Germany", 
                        "zip": "60316"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sankt Augustin", 
                        "country": "Germany", 
                        "zip": "53757"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667471"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rates according to the American College of Rheumatology criteria for juvenile idiopathic arthritis (JIA ACR)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Proportion of patients achieving inactive disease/clinical remission", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}